» Articles » PMID: 30544711

From Neuronal Differentiation of IPSCs to 3D Neuro-Organoids: Modelling and Therapy of Neurodegenerative Diseases

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2018 Dec 15
PMID 30544711
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

In the last decade, the advances made into the reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) led to great improvements towards their use as models of diseases. In particular, in the field of neurodegenerative diseases, iPSCs technology allowed to culture in vitro all types of patient-specific neural cells, facilitating not only the investigation of diseases' etiopathology, but also the testing of new drugs and cell therapies, leading to the innovative concept of personalized medicine. Moreover, iPSCs can be differentiated and organized into 3D organoids, providing a tool which mimics the complexity of the brain's architecture. Furthermore, recent developments in 3D bioprinting allowed the study of physiological cell-to-cell interactions, given by a combination of several biomaterials, scaffolds, and cells. This technology combines bio-plotter and biomaterials in which several types of cells, such as iPSCs or differentiated neurons, can be encapsulated in order to develop an innovative cellular model. IPSCs and 3D cell cultures technologies represent the first step towards the obtainment of a more reliable model, such as organoids, to facilitate neurodegenerative diseases' investigation. The combination of iPSCs, 3D organoids and bioprinting will also allow the development of new therapeutic approaches. Indeed, on the one hand they will lead to the development of safer and patient-specific drugs testing but, also, they could be developed as cell-therapy for curing neurodegenerative diseases with a regenerative medicine approach.

Citing Articles

Advances in hydrogel for diagnosis and treatment for Parkinson's disease.

Zhu P, Zhao Z, Gao Y Front Pharmacol. 2025; 16:1552586.

PMID: 40012627 PMC: 11860083. DOI: 10.3389/fphar.2025.1552586.


Transcriptomic and Functional Landscape of Adult Human Spinal Cord NSPCs Compared to iPSC-Derived Neural Progenitor Cells.

Jagadeesan S, Galuta A, Sandarage R, Tsai E Cells. 2025; 14(2).

PMID: 39851491 PMC: 11763936. DOI: 10.3390/cells14020064.


Neuroregeneration Improved by Sodium-D,L-Beta-Hydroxybutyrate in Primary Neuronal Cultures.

Ari C, DAgostino D, Cha B Pharmaceuticals (Basel). 2024; 17(9).

PMID: 39338322 PMC: 11435142. DOI: 10.3390/ph17091160.


Advances in current models on neurodegenerative diseases.

Pereira I, Lopez-Martinez M, Samitier J Front Bioeng Biotechnol. 2023; 11:1260397.

PMID: 38026882 PMC: 10658011. DOI: 10.3389/fbioe.2023.1260397.


scAAV9-VEGF alleviates symptoms of amyotrophic lateral sclerosis (ALS) mice through regulating aromatase.

Wang Y, Sun S, Zhai J, Liu Y, Song C, Sun C Exp Brain Res. 2023; 241(11-12):2817-2827.

PMID: 37882882 DOI: 10.1007/s00221-023-06721-7.


References
1.
Woodruff G, Reyna S, Dunlap M, van der Kant R, Callender J, Young J . Defective Transcytosis of APP and Lipoproteins in Human iPSC-Derived Neurons with Familial Alzheimer's Disease Mutations. Cell Rep. 2016; 17(3):759-773. PMC: 5796664. DOI: 10.1016/j.celrep.2016.09.034. View

2.
. Developmental alterations in Huntington's disease neural cells and pharmacological rescue in cells and mice. Nat Neurosci. 2017; 20(5):648-660. PMC: 5610046. DOI: 10.1038/nn.4532. View

3.
Domingo A, Klein C . Genetics of Parkinson disease. Handb Clin Neurol. 2018; 147:211-227. DOI: 10.1016/B978-0-444-63233-3.00014-2. View

4.
Mariani J, Coppola G, Zhang P, Abyzov A, Provini L, Tomasini L . FOXG1-Dependent Dysregulation of GABA/Glutamate Neuron Differentiation in Autism Spectrum Disorders. Cell. 2015; 162(2):375-390. PMC: 4519016. DOI: 10.1016/j.cell.2015.06.034. View

5.
Hsiao H, Chen Y, Huang C, Chen C, Hsu Y, Chen H . Aberrant astrocytes impair vascular reactivity in Huntington disease. Ann Neurol. 2015; 78(2):178-92. DOI: 10.1002/ana.24428. View